AXS26, April 26-30, 2026
Operating Under Observation: Privacy And Professionalism in a Recorded OR
Surgical ethics face new privacy and recording challenges testing clinician conduct and trust in modern medical spaces.
MAY 4, 2026
HOPA26, March 25-27, 2026
HOPA 2026: Emerging Off-Tumor Toxicities in CAR-T
Dr. Rebecca Gonzales discusses the incidence and mechanisms of novel toxicities due to off-tumor binding that may result in a systemic inflammatory response that drives unique events in hematologic patients receiving chimeric antigen receptor therapy.
APRIL 21, 2026
HOPA 2026: Updates in Small Cell Lung Cancer
Dr. Katie O’Reilly provides an update on treatments for both limited and extensive stages of small cell lung cancer and highlights practice-changing literature regarding t-cell engager therapy in extensive stage settings.
APRIL 13, 2026
HOPA 2026: Best Practices for Clinical Trials Across the Enterprise
Drs. Elyse MacDonald and Jennifer Murphy provide implementation strategies and best practices to navigate a successful clinical trial across the entire institutional enterprise.
APRIL 7, 2026
Happy National Oncology Pharmacists Day!
In honor of the inaugural National Oncology Pharmacists Day, PPN caught up with some HOPA attendees to ask how does an oncology pharmacist impact patient care and why the role so vital.
APRIL 3, 2026
HOPA 2026: 340B Drug Pricing Program Updates
Dr. Anthony Trovato provides an overview of the recent and ongoing updates to the 340B Drug Pricing Program, what to expect for the future of the program and shares insight on how to maintain compliance.
MARCH 31, 2026
Biosimilar Uptake Surges After Order Set Change at Academic Infusion Center
Biosimilar adoption study shows switching default oncology order sets to formulary biosimilars greatly increased utilization and improved cost ratios.
MARCH 30, 2026
A Synergy of CAR-T Hematotoxicity Scoring Tools
Cytopenia prediction strategies using CAR-HEMATOTOX and KyoTox show phase-specific strengths that aid precision risk assessment.
MARCH 30, 2026
4 Targeted Agents in 5 Years: BRAF/MEK Inhibitors Are Transforming Pediatric Oncology Pharmacy
Pediatric oncology pharmacists gain new targeted therapies for BRAF-altered tumors, improving outcomes and expanding treatment options for young patients.
MARCH 27, 2026
Gut Check: Gastric and Esophageal Cancer Treatment Evolves
Zolbetuximab for gastric and esophageal cancer improves survival but requires careful antiemetic management to reduce nausea and vomiting.
MARCH 27, 2026
GLP-1s in Oncology: Mixed Evidence and Shared Decision-Making
The evidence behind a boxed warning for thyroid cancer that has made many oncology clinicians wary of GLP-1 receptor agonists is weaker than most practitioners realize, experts said at HOPA 2026, in New Orleans.
MARCH 27, 2026
HOPA 2026: Role of GLP-1s in Oncology
Drs. Colleen McCabe and Lindsay Mundy discuss both the potential risks and benefits of GLP-1s for patients actively receiving cancer treatment.
MARCH 27, 2026
